Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 14, 2013 - Issue 14
Submit an article Journal homepage
864
Views
5
CrossRef citations to date
0
Altmetric
Editorial

Emerging approaches for the treatment of hypertriglyceridemia

Manfredi RizzoUniversity of Palermo, Biomedical Department of Internal Medicine and Medical Specialties, Via del Vespro, 141, 90127, Palermo, Italy+39 091 6552945; +39 091 6552945; [email protected];Euro-Mediterranean Institute of Science and Technology, Palermo, Italy
, MD PhD,
Pablo Perez-MartinezIMIBIC/Reina Sofia University Hospital/University of Cordoba, and CIBER Fisiopatologia Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, Lipids and Atherosclerosis Unit, Cordoba, Spain
,
Dragana NikolicUniversity of Palermo, Biomedical Department of Internal Medicine and Medical Specialties, Via del Vespro, 141, 90127, Palermo, Italy+39 091 6552945; +39 091 6552945; [email protected]
,
Giuseppe MontaltoUniversity of Palermo, Biomedical Department of Internal Medicine and Medical Specialties, Via del Vespro, 141, 90127, Palermo, Italy+39 091 6552945; +39 091 6552945; [email protected]
&
Jose Lopez-MirandaIMIBIC/Reina Sofia University Hospital/University of Cordoba, and CIBER Fisiopatologia Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, Lipids and Atherosclerosis Unit, Cordoba, Spain
Pages 1869-1873 | Published online: 06 Sep 2013

Bibliography

  • Rizzo M, Mikhailidis DP. There is more to predicting vascular disease than just established risk factors. Curr Pharm Des 2011;17:3608-10
  • Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011;9:258-70
  • Wierzbicki AS, Clarke RE, Viljoen A, Mikhailidis DP. Triglycerides: a case for treatment? Curr Opin Cardiol 2012;27:398-404
  • Kostapanos MS, Katsiki N, Elisaf MS, Mikhailidis DP. Editorial: reducing cardiovascular risk: is low-density lipoprotein-cholesterol (LDL-C) lowering enough? Curr Vasc Pharmacol 2012;10:173-7
  • Katsiki N, Nikolic D, Montalto G, et al. The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des 2013;19:3124-31
  • Superko HR, Berneis KK, Williams PT, et al. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. Am J Cardiol 2005;96:1266-72
  • Tziomalos K, Athyros VG, Mikhailidis DP. Fish oils and vascular disease prevention: an update. Curr Med Chem 2007;14:2622-8
  • Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308:1024-33
  • Meyers C, Gaudet D, Tremblay K, et al. The DGAT1 inhibitor LCQ908 decreases triglyceride levels in patients with the familial chylomicronemia syndrome. J Clin Lipidol 2012;6:266-7
  • Kostapanos MS, Rizos EC, Papanas N, et al. Mitochondrial triglyceride transfer protein inhibition: new achievements in the treatment of dyslipidemias. Curr Pharm Des 2013;19:3150-60
  • Rizzo M, Wierzbicki AS. New lipid modulating drugs: the role of microsomal transport protein inhibitors. Curr Pharm Des 2011;17:943-9
  • Rizzo M. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. IDrugs 2010;13:103-11
  • Wierzbicki AS, Hardman TC, Viljoen A. New lipid-lowering drugs: an update. Int J Clin Pract 2012;66:270-80
  • Kataoka Y, Uno K, Puri R, Nicholls SJ. Epanova((R)) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy. Future Cardiol 2013;9:177-86
  • Daily Med. VASCEPA® (icosapent ethyl) Capsules. 2012. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c1a2828-1583-4414-ab22-a60480e8e508 [Last accessed 10 June 2013]
  • Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-18
  • Anagnostis P, Katsiki N, Adamidou F, et al. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Metabolism 2013;62:21-33
  • Rizzo M, Berneis K. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. Curr Med Res Opin 2007;23:1103-11
  • Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-18
  • Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
  • American Diabetes Association. Standards of medical care in diabetes–2013. Diabetes Care 2013;36(Suppl 1):S11-66
  • Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br J Nutr 2012;107(Suppl 2):S201-13
  • Rizzo M, Barylski M, Rizvi AA, et al. Combined Dyslipidemia: should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia? Curr Pharm Des 2013;19:3858-68
  • Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011;9:533-71
  • AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. Am Heart J 2011;161:538-43

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.